Countries that prepare early protect lives, health systems, and economies
Along the border regions of Uganda and the Democratic Republic of Congo, a strain of Ebola for which no vaccine yet exists has claimed at least 277 lives and infected more than a thousand people, including children. In response, the global health community has mobilized — Gavi and Unicef committing up to $50 million to accelerate what has never been done before: the development of a Bundibugyo Ebolavirus vaccine. Kenya, untouched so far, has chosen vigilance over complacency, screening tens of thousands of travelers and preparing its health infrastructure as a quiet act of collective responsibility. This is the old tension of public health made vivid again — the race between human ingenuity and a virus that does not wait.
- A vaccine-less Ebola strain has killed 277 people and infected over 1,000 in eastern DRC and Uganda, with children among the dead and no approved medical countermeasure in sight.
- The absence of a Bundibugyo vaccine — unlike the stockpiled protection that exists for the Zaire strain — leaves an entire region exposed and creates a dangerous gap in global epidemic preparedness.
- Gavi and Unicef have issued an urgent global call to manufacturers, backed by up to $50 million, to identify the most promising vaccine candidates and scale production as fast as possible.
- Kenya has screened over 140,000 travelers and investigated more than 100 alerts since May, with all tests returning negative — a costly, deliberate effort to stay ahead of a threat that has not yet arrived.
- Manufacturers willing to produce vaccines on African soil will receive special consideration, signaling a broader ambition to build continental capacity rather than repeat the dependency patterns of past outbreaks.
A strain of Ebola with no approved vaccine is spreading across the border regions of Uganda and the Democratic Republic of Congo. At least 1,094 cases have been confirmed in eastern DRC, with 277 deaths — some of them children. This week, Gavi and Unicef announced a coordinated global push to change that reality, calling on vaccine developers and manufacturers worldwide to accelerate the creation of a Bundibugyo Ebolavirus shot that does not yet exist, backed by up to $50 million through Gavi's First Response Fund.
Kenya has recorded no cases, but the country is not waiting for one. Since May, the Ministry of Health has activated its national Ebola Incident Management System and screened more than 140,000 travelers arriving from affected areas. Over 100 suspected cases have been investigated. All have tested negative. Health Cabinet Secretary Aden Duale framed the logic clearly: early preparation protects people, health systems, and economies alike — and previous Ebola outbreaks have cost Africa billions in disrupted trade, tourism, and investment.
Behind Kenya's screening numbers lies a broader infrastructure — expanded laboratories, trained healthcare workers, stockpiled protective equipment, and isolation facilities built before they are needed. Duale invoked a deliberate image: fire stations exist before fires, not after.
The global vaccine initiative will be evaluated in partnership with the WHO and the Coalition for Epidemic Preparedness Innovations, with speed as the governing principle. One signal stands out: manufacturers proposing African production will receive special consideration. No stockpile exists for Bundibugyo as one does for the Zaire strain, and a vaccine developed and made on the continent could be deployed faster and build lasting local capacity. For now, Kenya watches, screens, and prepares.
A deadly strain of Ebola is spreading across the border regions of Uganda and the Democratic Republic of Congo, and Kenya is watching closely. At least 1,094 cases have been confirmed in eastern DRC alone, with 277 deaths—some of them children. There is no vaccine for this particular variant, called Bundibugyo Ebolavirus, which makes the situation urgent. This week, Unicef and Gavi announced a coordinated global effort to change that, issuing a call to vaccine manufacturers and developers worldwide to accelerate the creation and production of a shot that does not yet exist.
Kenya has not recorded a single case of Ebola, but the country is not waiting for one to appear. In May, the Ministry of Health activated its national Ebola Incident Management System and has been moving methodically through a checklist of preparedness measures. Health Cabinet Secretary Aden Duale explained the logic plainly: countries that prepare early protect their people, their health systems, and their economies. The math is straightforward. Previous Ebola outbreaks across Africa have cost billions in economic losses—disrupted travel, shuttered trade, collapsed tourism, frightened investors. Prevention is cheaper than crisis management.
The scale of Kenya's screening effort is substantial. Since May, the country has examined more than 140,000 travelers arriving from affected areas through airports and land borders. Health officials have investigated more than 100 suspected Ebola cases. All have tested negative. Behind these numbers sits a network of enhanced disease surveillance, expanded laboratory capacity, trained healthcare workers, stockpiled protective equipment, and isolation facilities prepared in advance. Duale used a deliberate metaphor: just as a city builds fire stations before fires occur, public health authorities must prepare quarantine facilities before outbreaks arrive.
The global vaccine initiative is substantial. Gavi has committed up to $50 million through its First Response Fund, with $40 million specifically earmarked to accelerate vaccine access. This week's announcement—a Request for Expression of Interest—is designed to identify which vaccine candidates show the most promise and which manufacturers can scale production fastest. Unicef and Gavi are working with the World Health Organization and the Coalition for Epidemic Preparedness Innovations to evaluate proposals. The process will be expedited. Speed matters when a virus is spreading.
One detail signals where the global health community hopes this effort will lead: manufacturers proposing to produce vaccines in Africa will receive special consideration. The current reality is stark. A global stockpile exists for vaccines against the Ebola Zaire strain, a different variant that has caused outbreaks before. No such stockpile exists for Bundibugyo. If a vaccine is developed and manufactured on the African continent, it could be deployed faster, reach more people, and build local capacity for future threats. Health experts say a successful vaccine would give Kenya and other East African countries a critical tool to contain outbreaks quickly, protect healthcare workers, and save lives. For now, Kenya waits and prepares.
Citas Notables
Countries that prepare early are better able to protect lives, safeguard their health systems and minimise disruption to their economies— Health Cabinet Secretary Aden Duale
Just as a country prepares fire engines before a fire occurs, public health authorities must prepare isolation and quarantine facilities before an outbreak occurs— Health Cabinet Secretary Aden Duale
La Conversación del Hearth Otra perspectiva de la historia
Why is Kenya preparing so intensively if there are no cases yet?
Because the virus is circulating next door. Uganda and the DRC are not distant—they share borders with Kenya. The regional threat is real, and history shows that early preparation saves lives and money.
What does "preparing" actually mean in practice?
It means screening travelers, training doctors, stockpiling protective gear, setting up isolation wards, and running disease surveillance networks. It means having the infrastructure ready before you need it.
Why does the vaccine development matter so much if Kenya hasn't had cases?
Because if the virus reaches Kenya, there will be no vaccine to stop it. Right now, there's no approved shot for this strain anywhere in the world. Developing one now, while there's still time, could prevent a catastrophe.
What's the significance of wanting African manufacturers involved?
It means the vaccine wouldn't have to be shipped from overseas. It could be made locally, stored locally, deployed immediately. It also builds African capacity for the next outbreak, whenever that comes.
How confident are health officials that Kenya will stay outbreak-free?
They're not predicting that. They're assuming the virus could arrive and preparing accordingly. That's the whole point—you don't wait for proof of danger. You act on the possibility.
What happens if a vaccine is developed but Kenya can't afford it?
That's why Gavi and Unicef are involved. They're global health organizations designed to ensure vaccines reach countries that need them, regardless of wealth. The $40 million commitment is partly about that access.